Benefits
Knee comfort and physical function
In a placebo-controlled trial, adults with knee osteoarthritis who took cetylated fatty acids by mouth for 68 days improved more on a knee function index than those on placebo, and a separate placebo-controlled trial of a cetyl myristoleate capsule over 12 weeks found lower knee pain and function scores at the doses that worked. Both trials were small and industry-supported.
Knee range of motion and flexibility
The 68-day oral trial measured knee flexion with a goniometer and reported a larger gain in the cetylated fatty acid group than in the placebo group, with no change in knee extension in either. This was one small trial in people already diagnosed with knee osteoarthritis, and it has not been repeated by an independent group; nothing in it looked at cartilage or joint fluid.
Joint pain, stiffness and physical function
A 30-day trial in adults with knee osteoarthritis gave one group oral cetylated fatty acids and the other a prescription anti-inflammatory tablet. Both groups improved from their own starting scores for pain, stiffness and function, with no significant difference between them. There was no placebo group, so the improvement cannot be credited to the supplement, and the study does not show the two are equivalent.
Topical cetylated fatty acid cream and knee mobility (applied to the skin)
In a 30-day trial, a cream containing cetylated fatty acids rubbed on the knee improved range of motion, stair climbing and a sit-to-stand test more than a placebo cream. A second cream also contained menthol, which relieves pain on its own, so its results cannot be credited to the fats. These are skin products on a separate footing and say nothing about what an oral capsule does.
Laboratory and animal research on joint inflammation
In cultured cells, a Celadrin cetylated fatty acid mixture lowered inflammatory signals (IL-6, MCP-1 and TNF) and nudged cells toward cartilage-type development. In rodents, the original report found protection against induced arthritis, a later study reproduced a smaller effect, and another laboratory could not reproduce it at all. These are cell and animal findings, not shown in people.
Mechanism of action
Proposed membrane and lubrication effect (not measured in people)
The main idea is that cetylated fatty acids are taken into cell membranes and joint tissue, where they are thought to improve lubrication and reduce friction. No human study of this ingredient has measured joint fluid volume, viscosity or lubrication, or whether osteoarthritis progresses more slowly, so this remains a hypothesis rather than a demonstrated action.
Shifting the fats available for inflammatory signals
The suggested anti-inflammatory route is that these fats change the fatty make-up of cell membranes, leaving less arachidonic acid for the enzymes that build inflammatory messengers. The only direct support comes from cultured cells, where a Celadrin mixture lowered IL-6, MCP-1 and TNF. Prostaglandin changes have not been shown in people taking it.
Cartilage-type cell behavior seen in a dish
In a laboratory study on cultured cells, the Celadrin fatty acid mixture pushed cells toward cartilage-type development while lowering inflammatory markers. Whether any of this happens inside a human joint is unknown; no trial has imaged or measured cartilage in people taking the ingredient, so there is no basis for a cartilage-repair claim.
Clinical trials
Randomized, double-blind, placebo-controlled trial of oral cetylated fatty acids (Celadrin) versus a vegetable-oil placebo over 68 days, with knee range of motion and the Lequesne functional index as outcomes (Hesslink et al. 2002, J Rheumatol).
64 adults with chronic knee osteoarthritis (33 cetylated fatty acids, 31 placebo).
After 68 days the cetylated fatty acid group gained more knee flexion than placebo (about 10.1 versus 1.1 degrees) and shifted more toward functional improvement on the Lequesne index (-5.4 versus -2.1 points); neither group improved knee extension. This is the only placebo-controlled oral trial, it was done in people already diagnosed with knee osteoarthritis, it has not been independently replicated, and the lead author was affiliated with the product.
Randomized, double-blind, placebo-controlled dose-finding trial of a cetyl myristoleate capsule product at three strengths versus a starch control over 12 weeks (Lee et al. 2017, Medicine (Baltimore)).
28 adults with mild knee joint pain, split across four small groups of 6 to 7 people.
Compared with the starch control, pain scores improved significantly in the full-strength group and in the lowest cetylated-ester group but not the middle one, and WOMAC scores fell in those two groups; most participants on the active products rated themselves improved. Groups held only 6 to 7 people each, and the study was funded by the capsule maker.
Randomized trial, without a placebo group, comparing oral cetylated fatty acids 350 mg three times daily for 30 days with the prescription anti-inflammatory meloxicam in knee osteoarthritis (Mohebi et al. 2023, Mediterr J Rheumatol).
48 adults with knee osteoarthritis divided into two groups.
Over follow-up to eight weeks after treatment, total WOMAC and Oxford Knee Scores did not differ significantly between the two groups, while both groups improved on pain, stiffness and function from their own baselines. With no placebo arm, the baseline improvement cannot be attributed to either treatment, and the trial does not show the supplement equals the medicine. No adverse events were reported in the cetylated fatty acid group.
Randomized, placebo-controlled trial of a cetylated fatty acid cream applied to the knee twice daily for 30 days, measuring range of motion, stair climbing, up-and-go and balance tests (Kraemer et al. 2004, J Rheumatol).
40 adults diagnosed with knee osteoarthritis (20 cream, 20 placebo cream).
The cream group improved more than the placebo cream group on knee range of motion, stair-climbing and up-and-go times, a step-down test and unilateral reach, both 30 minutes after the first use and after 30 days. Because this is a product rubbed on the skin, the results stand on a separate footing and do not show what an oral capsule does.
In vitro study of the Celadrin cetylated fatty acid mixture applied to cultured cells, measuring inflammatory mediators and cartilage-type differentiation (Hudita et al. 2020, Cartilage).
Cultured cells (human stem cells and mouse macrophage cells); no people were studied.
The mixture lowered the inflammatory mediators IL-6, MCP-1 and TNF and promoted cartilage-type cell development. These are cell-culture findings offered as a possible mechanism; they were not measured in anyone taking the supplement and do not establish a benefit in people.
Animal study isolating cetyl myristoleate from arthritis-resistant mice and testing it against adjuvant-induced arthritis in rats (Diehl et al. 1994, J Pharm Sci).
Laboratory rats with experimentally induced arthritis.
Cetyl myristoleate, isolated from mice or synthesized, gave good protection against adjuvant-induced arthritis in rats, while related esters gave less or no protection. This is the founding animal report behind the ingredient; dose and injection site mattered. It is an animal model, not evidence in people.
Animal study repeating the adjuvant-induced rat arthritis bioassay with cetyl myristoleate across several dosing schedules (Whitehouse et al. 1999, Inflammopharmacology).
Laboratory rats with adjuvant-induced polyarthritis.
Using an almost identical bioassay to the original 1994 report and several dosing schedules, the authors could not confirm an arthritis-preventing action of cetyl myristoleate. A separate group did reproduce a smaller effect in a different mouse arthritis model, so the animal evidence is inconsistent.